RenovoRx TIGeR-PaC Trial Surpasses 100 Patient Milestone
As of March 24, 2026, RenovoRx’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer has randomized 104 of...
Tonix Starts Phase 1 Trial for New Migraine Pain Treatment
Tonix Pharmaceuticals has dosed the first participant in an investigator-initiated Phase 1 study of TNX-1900, an intranasal, magnesium-potentiated oxytocin...
ORIC to Report Rinzimetostat Dose Data from mCRPC Trial
ORIC will detail combination dose optimization findings from its Phase 1b study of rinzimetostat (ORIC-944) in metastatic castration-resistant prostate...
GlucoTrack Targets Early Q2 For US FDA Clinical Trial Filing
Glucotrack’s first-in-human study of its fully implantable continuous blood glucose monitor reported a Mean Absolute Relative Difference of 7.7%...
First Patient Dosed in RAD 402 Advanced Prostate Cancer Trial
Radiopharm Theranostics has dosed the first patient in its first-in-human Phase 1 trial of RAD 402 in advanced prostate...
Biogen Drug Shows Promise in Phase 2 Cutaneous Lupus Trial
Litifilimab achieved clear or almost clear skin in 14.7% of patients at Week 16 versus 2.9% on placebo in...
Brepocitinib VALOR Trial Shows Positive Dermatomyositis Data
In the Phase 3 VALOR trial (n=241), brepocitinib 30 mg once-daily delivered a 15.3-point greater improvement in mean Total...
MoonLake Reveals New Sonelokimab HS Phase 3 Trial Results
At Week 40 in the Phase 3 VELA program for moderate-to-severe hidradenitis suppurativa (HS), sonelokimab achieved a 62% HiSCR75...
Spectral & Vantive Publish Tigris Trial Results in Lancet
In the Phase 3 Tigris trial of 157 adults with endotoxic septic shock, polymyxin B hemoadsorption (PMX) achieved a...
Minerva Presents Safety Trial Data on Roluperidone, Olanzapine
Minerva Neurosciences reported that an open-label safety study of roluperidone coadministered with olanzapine showed no clinically significant adverse effects...